CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0741 (clinicaltrials.gov NCT No: NCT01969838)
Title:A Phase 3, Randomized, Double-blind Active-controlled Study
Evaluating Momelotinib vs. Ruxolitinib in Subjects with
Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or
Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET
MF)
Principal Investigator:Srdan Verstovsek
Treatment Agent:Momelotinib; Ruxolitinib
Study Status:Open
Study Description:The goal of this clinical research study is to compare the effectiveness of
momelotinib to ruxolitinib when given to patients with PMF or Post-PV/ET MF.
The safety of these drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase III
Treatment Agents:Momelotinib
Ruxolitinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults